Transforming the early drug development paradigm at the National Cancer Institute: The formation of NCI’s Experimental Therapeutics Clinical Trials Network (ETCTN)

Early drug development for cancer requires broad collaboration and skilled clinical investigators to enable enrollment of patients whose tumors have defined molecular profiles. To respond to these challenges, the National Cancer Institute (NCI) transformed its 60-year old early phase drug developmen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Massett, Holly A., Mishkin, Grace, Moscow, Jeffrey A., Gravell, Amy, Steketee, Michael, Kruhm, Martha, Han, Sae H., Barry, Barbara, Montello, Michael, Zwiebel, James, Abrams, Jeffrey S., Doroshow, James H., Ivy, S. Percy
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891162/
https://ncbi.nlm.nih.gov/pubmed/31439585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1754
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares